Abstract
Correction of anemia in long-term hemodialysis patients by recombinant human erythropoetin (r-HuEPO) has been reported to improve sexual function. As elevated serum prolactin levels are believed to contribute to altered sexual function in uremia, we followed serum prolactin and testosterone levels during four months of r-HuEPO therapy. Within these four months, hematocrit values rose from 23.7± 1.2 to 35.7±0.2% and hemoglobin from 7.3±0.3 to 11.3±0.4 g/100 ml. In parallel, serum prolactin values decreased significantly, from 66.9± 9.3 to 9.6±2.6 ng/ml in females and from 39.5± 10.5 to 10.3± 1.0 ng/ml in male dialysis patients. Testosterone concentrations were in the lower normal range in male patients and remained unchanged during r-HuEPO therapy. Sexual function improved in four out of seven males, and five out of nine female patients started to have regular menstruations again. It appears that treatment of anemia in end-stage renal disease by r-HuEPO may improve sexual function by lowering elevated serum prolactin concentrations. (Int J Artif Organs 1989; 12:445-9)
Get full access to this article
View all access options for this article.